FDA Drug recall D-0237-2022
LOTRIMIN AF (Miconazole nitrate 2%) Jock Itch Powder Spray NET WT 133g (4.6 OZ) can, Dist by: Bayer Healthcare LLC, Whippany, NJ 07981, Pro…
- FDA Drug
- Class II
- terminated
- Published 2021-11-24
On 2021-11-24 the FDA classified a Class II recall of LOTRIMIN AF (Miconazole nitrate 2%) Jock Itch Powder Spray NET WT 133g (4.6 OZ) can, Dist by: Bayer Healthcare LLC, Whippany, NJ 07981, Pro… by Bayer Healthcare Pharmaceuticals, citing cGMP Deviations: manufactured at the same facility where other lots were found to be contaminated with benzene.
Read the official FDA Drug notice
| Agency | FDA Drug |
|---|---|
| Recall number | D-0237-2022 |
| Classification | Class II |
| Status | terminated |
| Initiated | 2021-10-01 |
| Published | 2021-11-24 |
| Last updated | 2026-09-13 11:52 UTC |
| Company | Bayer Healthcare Pharmaceuticals |
| Distribution | US |
Product
LOTRIMIN AF (Miconazole nitrate 2%) Jock Itch Powder Spray NET WT 133g (4.6 OZ) can, Dist by: Bayer Healthcare LLC, Whippany, NJ 07981, Product of Spain, NDC 11523-4140-2. UPC 3 11017 41031 8
Reason
cGMP Deviations: manufactured at the same facility where other lots were found to be contaminated with benzene.
Identifiers
| upc | 311017410318 |
|---|---|
| code_info | Lot #: CV01BEP, 3/31/2022; CV01D6W, 5/31/2022; CV01EV0, 7/31/2022; TN0004J, 9/30/2022; TN001AE, 11/30/2022; TN003C3, 1…Lot #: CV01BEP, 3/31/2022; CV01D6W, 5/31/2022; CV01EV0, 7/31/2022; TN0004J, 9/30/2022; TN001AE, 11/30/2022; TN003C3, 1/31/2023; TN003C4, 2/28/2023; TN003HT, 3/31/2023; TN003CW, 4/30/2023; TN0045J, 6/30/2023; TN0040C, 7/31/2023; TN004BU, 8/31/2023; TN006MB, 9/30/2022; |
Status history
No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: terminated.
Source
Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0237-2022%22
RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.